Skip to main content
padlock icon - secure page this page is secure

In vitro antitumor activity of Latcripin-15 regulator of chromosome condensation 1 domain protein

Buy Article:

$42.00 + tax (Refund Policy)

Cancer is one of the most significant health problems worldwide and thus the development of novel therapeutic agents with fewer side effects is required. The present study investigated the in vitro anticancer effects of a newly isolated fungal protein. In this study, Latcripin15 (LP15) regulator of chromosome condensation 1 (RCC1) domain protein, which is obtained from the Lentinula edodes C913 fungal strain, was identified, cloned, expressed, purified and refolded to assess the in vitro antitumor activity of the protein. LP15 RCC1 fulllength cDNA was isolated from Lentinula edodes using 3' and 5'rapid amplification of cDNA ends and then cloned, expressed, purified and refolded in vitro. In addition, the effects of the isolated LP15 RCC1 protein's functional domain on the viability and apoptosis of human lung cancer A549 cells were assessed by 3(4,5dimethylthiazol2yl)2,5diphenyltetrazolium bromide assay, transmission electron microscopy, flow cytometry and Hoechst 33258 staining. The LP15 RCC1 functional domain protein was successfully expressed, purified and refolded in vitro. Treatment with the LP15 RCC1 functional domain protein significantly reduced tumor cell viability and induced apoptosis in A549 cells. The results of the present study indicate that the LP15 RCC1 functional domain requires further investigation as a novel therapeutic agent for cancer therapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Department of Medical Microbiology, Dalian Medical University, Dalian, Liaoning 116044, P.R. China

Publication date: November 1, 2016

More about this publication?
  • Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.

    The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more